The company's year over year revenue growth was driven by continued growth in both its tuberculosis and tick-borne disease testing franchises.
The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals.
The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said.
A UK-led international consortium is sequencing tuberculosis genomes and cataloguing drug resistance mutations to enable more rapid NGS-based diagnostics.
Among the tests that French national health insurance system will reimburse are IGRA tests, including ones from Qiagen and Oxford Immunotec, for screening TB.
QuantiFeron-TB Gold Plus is an immunoassay that detects the release of interferon-gamma as a proxy for latent tuberculosis infection.
The company's tuberculosis business rose 8 percent, and its newly acquired tick-borne disease franchise notched $3.0 million in revenues during the quarter.
Quanterix's Simoa single-molecule detection method combined with high-affinity antibodies detected minute levels of problematic interferon alpha proteins, a study said.